• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Biotricity Inc.

    2/14/25 5:11:11 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care
    Get the next $BTCY alert in real time by email
    NT 10-Q 1 formnt10-q.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q

    ☐ Form N-SAR ☐ Form N-CSR

     

    For Period Ended: December 31, 2024

     

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

    ☐ Transition Report on Form N-SAR

     

    For the Transition Period Ended:

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission

    has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

     

    PART I - REGISTRANT INFORMATION

     

    BIOTRICITY INC.

    Full name of Registrant

     

    N/A

    Former Name if Applicable

     

    203 Redwood Shores Parkway, Suite 600

    Address of Principal Executive Office (Street and Number)

     

    Redwood City, CA 94065

    City, State and Zip Code

     

     

     

     

     

     

    PART II - RULE 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

     

      (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report portion thereof could not be filed within the prescribed time period.

     

    Biotricity Inc. (the “Company”) is unable to timely file its Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2024 (the “Form 10-Q”) within the prescribed time period due to its difficulty in completing and obtaining required financial and other information to be included in the Form 10-Q, which delay could not be eliminated by the Company without unreasonable effort and expense. The Company intends to file the Form 10-Q within the 5 calendar-day period set forth in Rule 12b-25(b) under the Securities Exchange Act of 1934, as amended.

     

    PART IV - OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

      John Ayanoglou (800)

    590-4155

      (Name) (Area Code) (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). Yes ☒ No ☐

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒

     

    If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    BIOTRICITY INC.

    (Name of Registrant as Specified in Charter)

     

    Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: February 14, 2025 By: /s/ Waqaas Al-Siddiq
       

    Waqaas Al-Siddiq

        Chief Executive Officer

     

     

     

    Get the next $BTCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTCY

    DatePrice TargetRatingAnalyst
    11/20/2023Buy → Neutral
    H.C. Wainwright
    3/7/2022$5.00Buy
    Lake Street
    11/23/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings